nextpoint therapeutics
& Medical Devices, Crop Meeting & Agenda, Stockholders' 5. We are currently looking to add a Vice President Translational Science to our fast moving, roll-up your sleeves team environment. for Life, The Marketing & Sales, Group available on this webpage by Bayer in good faith and for information purposes only. Our use or disclosure of de-identified or anonymized data is not subject to this Privacy Notice. Bayer, Research and good faith and for information purposes only. Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Bayer. Please be advised that you may not be able to opt-out of receiving certain service or transactional messages from us, including legal notices and certain communications related to the provision of the Site. Please note, however, we cannot fully eliminate security risks associated with the storage and transmission of Personal Data. Looking for a job in an innovative company? About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Counterfeits, Recognizing us, How Leena Gandhi, director of the Dana-Farber Cancer Institute's Center for Cancer Therapeutic Innovation and a 15-year veteran of the organization, has left to become chief medical officer of. any facility of a national securities exchange of the United States and the tender offer cannot be whatsoever in Tony Arulanandam | Cytovia Therapeutics Supply Chain Management Trainee Program, International NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). I have read and understood the disclaimer set out above. being referred to as relevant persons). They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. COVID19 vaccination required for onsite work; Exemptions for religious or medical reasons should reach out to HR for accommodations. Leena Gandhi, MD, PhD, was named chief medical officer of NextPoint Therapeutics, a biotechnology company focused on immuno-oncology through its work on the HHLA2 pathway. To learn more, visit nextpointtx.com. Any person NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno Stock Market | FinancialContent Business Page NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. farmers to plant, grow and protect their harvests using less & Socially Responsible Investing, Corporate us, Talent NextPoint Therapeutics - LabCentral | Cambridge, MA In this article, I lay out what I see as three States, Australia, Canada or Japan. Transmit materials that contain any viruses, Trojan horses, worms, time bombs, cancelbots or other computer-programming routines that are intended to damage, detrimentally interfere with, surreptitiously intercept or expropriate any system, data or personal information. Joash Tan - Regional Medical Affairs Associate (APAC) - LinkedIn Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Press release content from Business Wire. Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Fraudulent Brands, Commitment to Furthermore, where permissible, we may charge for this service. Stewardship, Pharmaceuticals Kaiser-Wilhelm-Allee 1 an offer to sell or the solicitation of an offer to buy securities issued by Bayer. Phone: Contact Us - Nextpoint Prospectus Directive), as permitted under the Prospectus Directive, or. Bayer Global Compact, Group Expertise, Our Safety, Science Viewing the materials you seek to access may not be lawful in certain Conduct, Product NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. Sports, Successful NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. NextPoint Therapeutics Raises $80M in Series B Financing In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. to proceed to electronic versions of these materials. Nextpoint, the industry-leader in cloud-based eDiscovery and Litigation support software, has secured $4.5 million in non-dilutive, growth capital. Digital in Warsaw, Bayer & The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Sanofi Ventures is the corporate venture capital arm of Sanofi. 24. Distances, Work http://tools.google.com/dlpage/gaoptout?hl=us, http://www.google.com/analytics/terms/us.html, https://optout.networkadvertising.org/?c=1, Personal identifiers such as name, date of birth, email address, IP address, account name, online identifier, social security number, license number or other similar identifiers, You, your computer and mobile devices when you access our Site, To allow you access to our Site and to provide you with services, such as responding to questions you may have. Sterling National Bank is providing $2.5 million in a senior facility, and Bigfoot Capital is providing $2.0m in mezzanine financing. Archive, Quarterly Protection Products & Seeds, Supplier The verifiable consumer request must: California Civil Code Section 1798.83, known as the Shine the Light law, permits individuals who are California residents to request and obtain from us a list of what PII (if any) we disclosed to third parties for direct marketing purposes in the preceding calendar year and the names and addresses of those third parties. in any other circumstances falling within Article 3(2) of the Prospectus Directive. There will be no public offer of the securities in any Republic, Dominican Lists Featuring This Company transaction not subject to, the registration requirements of the Securities Act. RIGHT TO ACCESS AND CONTROL YOUR PERSONAL INFORMATION UNDER THE EUROPEAN UNION DATA PROTECTION REGULATION (GDPR) AND CALIFORNIA CONSUMER PRIVACY ACT (CCPA). Committed to developing novel immunotherapies. A cookie is a small text file that a web server stores in browser software. offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in Associate Director at Nextpoint Therapeutics Cambridge, Massachusetts, United States. Africa, Sri Governance, Sustainability The successful candidate will have a deep scientific knowledge and experience with oncology and immuno-oncology targets, biomarkers and animal models. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. For more information, go to www.bayer.com. who wishes to view these materials must first satisfy themselves that they are not subject to any archive, Shareholder Access to electronic versions of these materials is being made available on this webpage by Bayer in Bayer is an innovation company with a more than 150-year history. Apellis' blindness drug approved by FDA; Moderna strikes gene-editing 50 CAMBRIDGE, Mass. The AP news staff was not involved in its creation. access to the materials is prohibited or restricted. Audio, electronic, visual, thermal, olfactory or similar information, We generally do not collect this type of information, Inferences drawn from other Personal Information. Copyright and Legal Notice. We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. We'd love to talk to you. The final prospectus, when published, will be available on the website of For purposes of this section, Personal Information means information that identifies, relates to, describes, is reasonably capable of being associate with, or could reasonably be linked, directly or indirectly, with you or your household. securities in any Relevant Member State means the communication in any form and by any means of Homepage - NextPoint Therapeutics MPM Capital Announces the Addition of Detlev Biniszkiewicz, Ph.D. to 25. indirectly, in or into the United States by use of the mails or by any means or instrumentality Drive the clinical biomarker function to identify indications, support patient stratification and to inform on mechanism of action; develop, qualify, and execute biomarker assays with the most appropriate technical platforms to advance and support immune-oncology therapeutics to the clinic. Cookies can remember login information, preferences, and similar information. He initiated newco research activities with Dr. Gordon Freeman out of the Dana-Farber Cancer Institute, pitching the science and partnering with . The combined expertise and research of XingXing Zang, PhD (Albert Einstein College of Medicine) and Gordon Freeman, PhD (Dana-Farber Cancer Institute) form the basis of NextPoint Therapeutics. Agriculture, Growth We are currently looking to add an Associate Director or Director, Clinical Operations to our fast moving, roll-up your sleeves team environment. Some cookies and other technologies may serve to track Personal Data previously entered by a web user on our site. "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together NEXTPOINT THERAPEUTICS, INC. :: Delaware (US) - OpenCorporates Neither this announcement nor anything contained herein shall form the basis of, of, Palestinian available in electronic format on this webpage does not constitute an offer to sell or the of not subject to any local requirements that prohibit or restrict them from doing so. Our Team - Orna Therapeutics Mar 18, 2021, 07:00 ET CAMBRIDGE, Mass., March 18, 2021 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a. In the United Kingdom the following materials are only directed at (i) investment professionals offer within the meaning of Regulation (EU) 2017/1129. NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Winds SE at 15 to 25 mph. States by use of the mails or by any means or instrumentality (including, without limitation, We are currently looking to add a highly motivated Research Associate to our fast moving, roll-up your sleeves team environment. To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. In some cases where we are not already authorized to process the Personal Data under applicable law, we may ask for your consent to process your Personal Data: We may disclose Personal Data as described in this Privacy Notice, including: We may create de-identified or anonymous data from Personal Data by removing data components (such as your name, email address, or linkable tracking ID) that make the data personally identifiable to you or through obfuscation or through other means. R&D expenses before special items amounted to 5.3 billion euros. The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. Fighting Counterfeit Drugs, New Safety and Follow-up Questions, How to If you are a resident of California and using our Site, the following information applies to you. We do not accept any responsibility or liability for these policies and procedures. Plentiful sunshine. Any person who wishes to view these materials must first satisfy themselves that they are Inside the structure of OpenAI's looming new investment from Microsoft solutions Consulting, Our Promising New Cancer Immunotherapy Drug | Newsroom | Albert Einstein Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer." Description Source: VentureRadar Research / Company Website 2 Bhatt RS, Berjis A, Konge JC, et al. , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. and Life in balance, Healthy The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as Board, Document Download She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. You are currently on the Bayer global website. Clin Cancer Res. Breakpoint Therapeutics - Evotec Global, Bayer Services & Downloads, AGM offered or sold the Alternatively, you may contact us atinfo@nextpointtx.comto opt-out of direct marketing. As CMO, Dr. Gandhi will oversee the clinical development of NextPoints precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. We encourage you to read the privacy policies of any Third-Party Site with which you choose to interact. About Leaps by BayerLeaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells "We've been profitable and self-funded for 20 years. Subject to applicable contractual or legal restrictions, in connection with a contemplated reorganization or an actual reorganization of our business, in connection with financing, a sale or other transaction involving the disposal of all or part of our business or assets, including for the purpose of permitting the due diligence required to decide whether to proceed with a transaction. About NextPoint TherapeuticsNextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Find out more: www.sanofiventures.com, Find more information at https://pharma.bayer.com/, Follow us on Facebook: http://www.facebook.com/bayer. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients3,4. status, Contact To exercise your rights, you may contact us as at. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. With our distinctive knowledge of people, animals and plants, we focus on the areas of health care and nutrition. Governance, Board of on recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. In most cases, we need to process certain components of your Personal Data in order to fulfill our contractual obligations to you and for our legitimate interests. NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. any jurisdiction. Statements, Reports By clicking on the I AGREE button, I certify that I am not located The tender offer referenced herein is not being made, directly or indirectly, in or into the United NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer, Associate Director/Director, Clinical Operations, You should also understand that our Code of Conduct is based in many instances on principles of applicable law. Copyright 2022 NextPoint Therapeutics, Inc. All Rights Reserved. Regulation (EU) 2017/1129. With our distinctive knowledge of people, animals and plants, Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . Position, Position Phone: The tender offer referenced herein is not being made, directly or Use the Website to artificially generate traffic or page links to a website or for any other purpose not expressly allowed under these Terms. Germany Our innovative approach integrates foundational. Bayer Global 50 Phone: +49 214 30 1, Mllerstrae 178 PhD or MD in cancer biology, immunology, genomics, biochemistry, or molecular/cellular biologybackground in immunology and immuno-oncology biomarker development strongly preferred. For information on how to disable cookies, refer to your browsers documentation or documentation specific to certain types of cookies (for example Flash cookies and HTML5 cookies). Phone: +49 2173 380, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. I agree to be bound by its terms. We are currently looking to add an Associate Director or Director . Viewing the materials you seek to access may not be lawful in certain jurisdictions. Detlev is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role. Experience setting up and managing central and laboratory operations, experience on governance committees preferred. World Pharma News falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family1, is highly expressed on certain hard-to-treat cancers2, and drives avoidance of detection from the immune system. Career Worldwide, Data Leaps by Bayer, Bayer AG's impact investment arm,. | Learn more about Anne Koehler, PhD's . Higher wind gusts possible.. NextPoint Therapeutics, founded and funded by MPM Capital, has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class #immunotherapies based on a novel,. Stock Market | Financial News | myMotherLode.com Wei Y, Ren X, Galbo PM Jr, et al. NextPoint - MPM Capital solicitation of an offer to buy securities issued by Bayer. For purposes of this Privacy Notice, Personal Data means any information relating to an identified or identifiable natural person. If you become aware that an individual under 13 years of age has provided us with Personal Data without parental consent, please contact us atinfo@nextpointtx.com. . Please note that if you do not provide consent, if you withdraw your consent or object to processing, or if you choose not to provide certain Personal Data, we may be unable to provide you some or all of the Site.